J&J rises about 1% after AbbVie myeloma drug 74% response
Johnson & Johnson rose roughly 1% to $277.955 Thursday afternoon after AbbVie’s experimental multiple-myeloma drug etentamig showed a 74% response rate, lowering the risk of disease progression or death.
Johnson & Johnson NYSE:JNJ, the pharmaceutical and medical-technology powerhouse, rose roughly 1% to $277.955 Thursday afternoon.
Investors barely flinched after AbbVie's experimental multiple-myeloma drug, etentamig, produced a 74% response rate and lowered the risk of disease progression or death…